DNB Asset Management AS Has $64.79 Million Stake in Humana Inc. (NYSE:HUM)

DNB Asset Management AS boosted its holdings in shares of Humana Inc. (NYSE:HUM – Get Rating) by 222.0% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 126,496 shares of the insurance provider’s stock after purchasing an additional 87,213 shares during the period. DNB Asset Management AS owned 0.10% of Humana worth $64,790,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of HUM. Castleview Partners LLC increased its holdings in Humana by 46,704.0% during the 2nd quarter. Castleview Partners LLC now owns 11,701 shares of the insurance provider’s stock valued at $25,000 after purchasing an additional 11,676 shares in the last quarter. Insight Inv LLC acquired a new stake in shares of Humana in the 2nd quarter valued at $47,000. Ronald Blue Trust Inc. acquired a new stake in shares of Humana in the 2nd quarter valued at $49,000. Accurate Wealth Management LLC acquired a new stake in shares of Humana in the 4th quarter valued at $55,000. Finally, CoreCap Advisors LLC acquired a new stake in shares of Humana in the 2nd quarter valued at $59,000. 93.38% of the stock is owned by institutional investors and hedge funds.

Humana Trading Up 0.2 %

HUM stock traded up $1.17 during midday trading on Friday, hitting $495.55. 1,962,747 shares of the company’s stock were exchanged, compared to its average volume of 851,645. The stock’s fifty day moving average price is $494.78 and its 200-day moving average price is $507.54. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.52 and a current ratio of 1.52. The company has a market cap of $61.93 billion, a PE ratio of 22.48, a price-to-earnings-growth ratio of 1.24 and a beta of 0.72. Humana Inc. has a one year low of $410.87 and a one year high of $571.30.

Humana (NYSE:HUM – Get Rating) last released its quarterly earnings results on Wednesday, February 1st. The insurance provider reported $1.62 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.46 by $0.16. Humana had a return on equity of 20.50% and a net margin of 3.02%. The firm had revenue of $22.44 billion for the quarter, compared to the consensus estimate of $22.45 billion. During the same quarter last year, the business posted $1.24 EPS. The company’s revenue for the quarter was up 6.6% on a year-over-year basis. Research analysts predict that Humana Inc. will post 28.05 earnings per share for the current fiscal year.

Humana Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, April 28th. Shareholders of record on Friday, March 31st will be paid a $0.885 dividend. This is an increase from Humana’s previous quarterly dividend of $0.79. The ex-dividend date of this dividend is Thursday, March 30th. This represents a $3.54 annualized dividend and a dividend yield of 0.71%. Humana’s dividend payout ratio (DPR) is currently 14.29%.

Analyst Ratings Changes

Several research firms have recently commented on HUM. Credit Suisse Group lowered their target price on Humana from $635.00 to $575.00 and set an “outperform” rating for the company in a research note on Monday, February 6th. The Goldman Sachs Group raised Humana from a “neutral” rating to a “buy” rating and lifted their target price for the company from $575.00 to $652.00 in a research note on Tuesday, December 13th. Cowen lowered their target price on Humana from $647.00 to $581.00 and set an “outperform” rating for the company in a research note on Monday, February 6th. Stephens reduced their price target on Humana from $625.00 to $590.00 and set an “overweight” rating on the stock in a research report on Friday, February 3rd. Finally, UBS Group reduced their price target on Humana from $645.00 to $620.00 and set a “buy” rating on the stock in a research report on Thursday, February 2nd. Two equities research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $594.12.

Insider Buying and Selling at Humana

In related news, insider Joseph C. Ventura sold 2,048 shares of Humana stock in a transaction dated Monday, February 27th. The stock was sold at an average price of $507.97, for a total value of $1,040,322.56. Following the sale, the insider now owns 4,256 shares of the company’s stock, valued at $2,161,920.32. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, insider Joseph C. Ventura sold 2,048 shares of Humana stock in a transaction dated Monday, February 27th. The stock was sold at an average price of $507.97, for a total value of $1,040,322.56. Following the sale, the insider now owns 4,256 shares of the company’s stock, valued at $2,161,920.32. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Bruce D. Broussard sold 17,575 shares of Humana stock in a transaction dated Monday, February 27th. The shares were sold at an average price of $505.85, for a total value of $8,890,313.75. Following the completion of the sale, the chief executive officer now directly owns 70,040 shares in the company, valued at approximately $35,429,734. The disclosure for this sale can be found here. Insiders have sold 34,623 shares of company stock valued at $17,456,436 in the last 90 days. 0.39% of the stock is currently owned by company insiders.

About Humana

(Get Rating)

Humana Inc engages in the provision of health insurance services. It operates through the Insurance and CenterWell segments. The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as contract with CMS to administer the Limited Income Newly Eligible Transition, or LI-NET, prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits, which refer to as state-based contracts.